A DOUBLE-BLIND, RANDOMIZED, ACTIVE-COMPARATOR (METFORMIN) CONTROLLED, CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE STRATEGY TO START PATIENTS WITH TYPE 2 DIABETES MELLITUS ON JANUMET™ COMPARED TO METFORMIN: